Pharma-Biotech Capital Construction 2015 Investment Review: $15 Billion in 2015 Project Kick-Offs, an Industrial Info News Alert
(firmenpresse) - SUGAR LAND, TX -- (Marketwired) -- 01/11/16 -- Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- With 2016 in its earliest days, let''s take look back at some of the high points in 2015. A recent analysis of reported projects that began in 2015, derived from Industrial Info''s , has revealed that the North American Pharmaceutical & Biotech Industry kicked off a healthy $15 billion worth of construction activity.
Within this article: Frederick, Maryland manufacturing center expansion by AstraZeneca (NYSE:AZN) and intravenous biologics plant project by Gilead Sciences (NASDAQ:GILD).
For details, , or browse other breaking industrial news stories at .
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, five offices in North America and 10 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info''s quality-assurance philosophy, the Living Forward Reporting Principle™, provides up-to-the-minute intelligence on what''s happening now, while constantly keeping track of future opportunities. To contact an office in your area, visit the "" page.
Contact:
Brian Ford
713-783-5147
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 11.01.2016 - 06:30 Uhr
Sprache: Deutsch
News-ID 1408017
Anzahl Zeichen: 1632
contact information:
Contact person:
Town:
SUGAR LAND, TX
Phone:
Kategorie:
Machinery & Tools
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 324 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Pharma-Biotech Capital Construction 2015 Investment Review: $15 Billion in 2015 Project Kick-Offs, an Industrial Info News Alert
"
steht unter der journalistisch-redaktionellen Verantwortung von
Industrial Info Resources (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
